Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN)
In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca, with a price target of £163.70.
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and DBV Technologies SA – American. According to TipRanks, Sharma has an average return of 3.7% and a 55.05% success rate on recommended stocks.
In addition to Goldman Sachs, AstraZeneca also received a Buy from J.P. Morgan’s Richard Vosser in a report issued yesterday. However, on the same day, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).
Based on AstraZeneca’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p15.29 billion and a net profit of p3.08 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p3 billion
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.
Read More on GB:AZN:
Disclaimer & DisclosureReport an Issue
- AI Daily: Amazon’s AWS commits $1B toward new unit
- Anthropic takes aim at pharma industry with Claude Science, STAT reports
- AstraZeneca Expands Metastatic Prostate Cancer Pipeline With New Platform Trial
- AstraZeneca: Buy Rating Reiterated on Robust Pipeline Upside and Solid Execution; Price Target Unchanged at 16,500 GBp
- AstraZeneca Advances AI-Driven Lung Cancer Risk Study in Brazil
